DR-414 Neoantigen discovery and validation for therapeutic vaccine development

Developing effective cancer therapies is challenging, often benefiting only specific patient groups. The Oncode Accelerator consortium aims to innovate this process. Within the Van Heesch group, we contribute to the development of therapeutic vaccines. We focus on discovering unique genetic changes in cancer cells that can lead to the production of abnormal proteins. These proteins, when specific to cancer, can be targeted by the immune system. By analyzing genetic data from a diverse patient population, including the extensive Hartwig Medical Foundation database, we aim to identify and validate potential vaccine targets. This approach could lead to more personalized and effective cancer treatments for a wider range of patients.

Sebastiaan van Heesch, Prinses Maxima Centrum, the Netherlands